EXACT Sciences Company Profile (NASDAQ:EXAS)

About EXACT Sciences (NASDAQ:EXAS)

EXACT Sciences logoExact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:EXAS
  • CUSIP: 30063P10
  • Web: www.exactsciences.com
  • Market Cap: $3.55 billion
  • Outstanding Shares: 111,192,000
Average Prices:
  • 50 Day Moving Avg: $28.01
  • 200 Day Moving Avg: $20.50
  • 52 Week Range: $5.72 - $36.14
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -34.67
  • P/E Growth: -0.35
Sales & Book Value:
  • Annual Revenue: $132.9 million
  • Price / Sales: 26.69
  • Book Value: $2.78 per share
  • Price / Book: 11.47
  • EBIDTA: ($144,340,000.00)
  • Net Margins: -216.45%
  • Return on Equity: -55.44%
  • Return on Assets: -49.29%
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 11.94%
  • Quick Ratio: 11.69%
  • Average Volume: 3.06 million shs.
  • Beta: 0.84
  • Short Ratio: 10

Frequently Asked Questions for EXACT Sciences (NASDAQ:EXAS)

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings data on Thursday, April, 27th. The company reported ($0.32) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.09. The business had revenue of $48.36 million for the quarter, compared to the consensus estimate of $37.38 million. EXACT Sciences had a negative return on equity of 55.44% and a negative net margin of 216.45%. The firm's revenue was up 225.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.49) EPS. View EXACT Sciences' Earnings History.

Where is EXACT Sciences' stock going? Where will EXACT Sciences' stock price be in 2017?

14 brokers have issued 1 year price objectives for EXACT Sciences' shares. Their forecasts range from $8.00 to $45.00. On average, they expect EXACT Sciences' share price to reach $27.31 in the next year. View Analyst Ratings for EXACT Sciences.

What are analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:

  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (4/25/2017)
  • 2. Cowen and Company analysts commented, "Colon cancer is the #2 cause of cancer death in the US, yet compliance with screening guidelines is low. Exact Sciences' Cologuard is less invasive than colonoscopy, more accurate than alternatives, FDA approved, in guidelines, and increasingly reimbursed. EXAS is targeting $4B of a ~$15B annual market opportunity. The 5-year revenue CAGR is forecast at ~50%. Initiate at Outperform with a $30 PT." (3/27/2017)

Are investors shorting EXACT Sciences?

EXACT Sciences saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 30,407,001 shares, an increase of 2.2% from the April 13th total of 31,100,033 shares. Based on an average trading volume of 3,723,223 shares, the short-interest ratio is currently 8.2 days. Currently, 28.0% of the shares of the company are short sold.

Who are some of EXACT Sciences' key competitors?

Who owns EXACT Sciences stock?

EXACT Sciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.88%), BlackRock Inc. (6.12%), JPMorgan Chase & Co. (4.48%), State Street Corp (4.18%), Primecap Management Co. CA (4.04%) and William Blair Investment Management LLC (3.69%). Company insiders that own EXACT Sciences stock include D Scott Coward, David Thompson, Graham Peter Lidgard, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy, Lionel Sterling and Maneesh Arora. View Institutional Ownership Trends for EXACT Sciences.

Who sold EXACT Sciences stock? Who is selling EXACT Sciences stock?

EXACT Sciences' stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, William Blair Investment Management LLC, State Street Corp, Gilder Gagnon Howe & Co. LLC, Columbia Wanger Asset Management LLC, J&P China Capital Management CO. Ltd., Kornitzer Capital Management Inc. KS and Morgan Stanley. Company insiders that have sold EXACT Sciences stock in the last year include D Scott Coward, Graham Peter Lidgard, Kevin T Conroy and Maneesh Arora. View Insider Buying and Selling for EXACT Sciences.

Who bought EXACT Sciences stock? Who is buying EXACT Sciences stock?

EXACT Sciences' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Point72 Asset Management L.P., OppenheimerFunds Inc., Perceptive Advisors LLC, Vanguard Group Inc., Mackenzie Financial Corp and Renaissance Technologies LLC. Company insiders that have bought EXACT Sciences stock in the last two years include David Thompson, James Edward Doyle, Katherine S Napier, Katherine S Zanotti, Kevin T Conroy and Lionel Sterling. View Insider Buying and Selling for EXACT Sciences.

How do I buy EXACT Sciences stock?

Shares of EXACT Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of EXACT Sciences stock cost?

One share of EXACT Sciences stock can currently be purchased for approximately $31.90.

Analyst Ratings

Consensus Ratings for EXACT Sciences (NASDAQ:EXAS) (?)
Ratings Breakdown: 3 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $27.31 (14.40% downside)

Analysts' Ratings History for EXACT Sciences (NASDAQ:EXAS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Jefferies Group LLCReiterated RatingBuy$35.00LowView Rating Details
5/15/2017Cowen and CompanyBoost Price TargetOutperform$40.00 -> $45.00N/AView Rating Details
5/1/2017Goldman Sachs Group IncSet Price TargetNeutral$21.00 -> $33.00MediumView Rating Details
4/28/2017Leerink SwannSet Price TargetBuy$38.00MediumView Rating Details
4/24/2017Canaccord GenuityReiterated RatingBuy$27.00LowView Rating Details
3/29/2017Bank of America CorpReiterated RatingBuyHighView Rating Details
3/27/2017Craig HallumSet Price TargetBuy$28.00HighView Rating Details
2/22/2017Roth CapitalUpgradeNeutral -> Buy$15.00 -> $26.00N/AView Rating Details
2/21/2017Benchmark Co.UpgradeHold -> Buy$17.00 -> $27.00N/AView Rating Details
1/8/2017BTIG ResearchReiterated RatingBuy$22.00N/AView Rating Details
12/20/2016Robert W. BairdSet Price TargetBuy$22.00N/AView Rating Details
11/1/2016Lake Street CapitalLower Price TargetHold$15.00 -> $8.00N/AView Rating Details
7/27/2016MizuhoBoost Price TargetNeutral$10.00 -> $15.00N/AView Rating Details
7/15/2016William BlairReiterated RatingOutperform$29.00N/AView Rating Details
2/25/2016StephensDowngradeOverweight -> Equal WeightN/AView Rating Details
10/30/2015WedbushLower Price Target$7.00 -> $6.50N/AView Rating Details
(Data available from 5/24/2015 forward)


Earnings History for EXACT Sciences (NASDAQ:EXAS)
Earnings by Quarter for EXACT Sciences (NASDAQ:EXAS)
Earnings History by Quarter for EXACT Sciences (NASDAQ:EXAS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017($0.41)($0.32)$37.38 million$48.36 millionViewN/AView Earnings Details
2/21/2017Q416($0.39)($0.34)$32.53 million$35.24 millionViewListenView Earnings Details
10/26/2016Q316($0.43)($0.36)$25.24 million$28.10 millionViewListenView Earnings Details
7/26/2016Q216($0.55)($0.46)$18.54 million$21.20 millionViewListenView Earnings Details
5/3/2016Q116($0.52)($0.49)$15.17 million$14.80 millionViewN/AView Earnings Details
2/24/2016Q415($0.47)($0.41)$14.96 million$14.40 millionViewListenView Earnings Details
10/29/2015Q315($0.44)($0.45)$12.56 million$12.60 millionViewListenView Earnings Details
7/20/2015Q215($0.45)($0.44)$7.96 million$8.10 millionViewListenView Earnings Details
5/4/2015Q115($0.41)($0.40)$4.11 million$4.30 millionViewN/AView Earnings Details
2/24/2015Q414($0.39)($0.38)$19.90 million$1.15 millionViewN/AView Earnings Details
10/27/2014Q314($0.34)($0.39)$0.13 millionViewListenView Earnings Details
7/22/2014Q214($0.25)($0.24)$0.03 millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.23)$0.40 million$0.30 millionViewN/AView Earnings Details
2/20/2014Q413($0.19)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
10/29/2013Q313($0.18)($0.16)$1.02 million$1.00 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.18)($0.19)$1.02 million$1.00 millionViewN/AView Earnings Details
5/1/2013Q1 2013($0.20)($0.17)$1.02 million$1.00 millionViewN/AView Earnings Details
2/20/2013Q4 2012($0.18)($0.22)$1.04 million$1.00 millionViewN/AView Earnings Details
10/30/2012Q312($0.21)($0.21)$1.03 million$1.04 millionViewN/AView Earnings Details
7/25/2012($0.20)($0.26)ViewN/AView Earnings Details
5/1/2012($0.18)($0.19)ViewN/AView Earnings Details
2/23/2012($0.17)($0.18)ViewN/AView Earnings Details
11/3/2011($0.15)($0.15)ViewN/AView Earnings Details
8/2/2011($0.10)($0.13)ViewN/AView Earnings Details
5/3/2011($0.09)($0.08)ViewN/AView Earnings Details
2/15/2011($0.08)($0.08)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for EXACT Sciences (NASDAQ:EXAS)
2017 EPS Consensus Estimate: ($1.46)
2018 EPS Consensus Estimate: ($0.83)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.44)($0.40)($0.42)
Q2 20174($0.41)($0.33)($0.38)
Q3 20174($0.38)($0.28)($0.33)
Q4 20174($0.36)($0.30)($0.33)
Q1 20181($0.26)($0.26)($0.26)
Q2 20181($0.22)($0.22)($0.22)
Q3 20181($0.18)($0.18)($0.18)
Q4 20181($0.17)($0.17)($0.17)
Q1 20191($0.14)($0.14)($0.14)
(Data provided by Zacks Investment Research)


Dividend History for EXACT Sciences (NASDAQ:EXAS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for EXACT Sciences (NASDAQ:EXAS)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 86.54%
Insider Trades by Quarter for EXACT Sciences (NASDAQ:EXAS)
Institutional Ownership by Quarter for EXACT Sciences (NASDAQ:EXAS)
Insider Trades by Quarter for EXACT Sciences (NASDAQ:EXAS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017D Scott CowardSVPSell1,543$23.74$36,630.82View SEC Filing  
3/13/2017D Scott CowardSVPSell1,983$21.16$41,960.28View SEC Filing  
3/13/2017Kevin T ConroyInsiderSell12,059$21.16$255,168.44View SEC Filing  
3/13/2017Maneesh AroraCOOSell5,574$21.16$117,945.84View SEC Filing  
2/27/2017D Scott CowardSVPSell7,046$21.48$151,348.08View SEC Filing  
2/27/2017Graham Peter LidgardInsiderSell8,668$21.51$186,448.68View SEC Filing  
2/27/2017Maneesh AroraCOOSell11,114$21.50$238,951.00View SEC Filing  
1/3/2017D Scott CowardSVPSell1,535$13.61$20,891.35View SEC Filing  
12/14/2016David ThompsonDirectorBuy10,000$13.84$138,400.00View SEC Filing  
11/15/2016Kevin T ConroyInsiderSell600,000$17.46$10,476,000.00View SEC Filing  
11/15/2016Maneesh AroraCOOSell562,932$17.46$9,828,792.72View SEC Filing  
9/1/2016Lionel SterlingDirectorBuy5,000$18.10$90,500.00View SEC Filing  
8/3/2016Katherine S ZanottiDirectorBuy3,380$17.93$60,603.40View SEC Filing  
7/26/2016Graham Peter LidgardInsiderSell7,383$14.82$109,416.06View SEC Filing  
7/26/2016Maneesh AroraCOOSell7,359$14.82$109,060.38View SEC Filing  
4/1/2016D Scott CowardSVPSell1,685$6.62$11,154.70View SEC Filing  
3/10/2016D Scott CowardSVPSell2,175$6.05$13,158.75View SEC Filing  
3/10/2016Graham Peter LidgardInsiderSell3,041$6.05$18,398.05View SEC Filing  
3/10/2016Maneesh AroraCOOSell4,042$6.05$24,454.10View SEC Filing  
3/8/2016James Edward DoyleDirectorBuy5,000$6.43$32,150.00View SEC Filing  
3/3/2016Katherine S NapierDirectorBuy3,775$5.38$20,309.50View SEC Filing  
3/1/2016Kevin T ConroyCEOBuy50,000$5.00$250,000.00View SEC Filing  
2/26/2016Kevin T ConroyCEOSell6,895$5.81$40,059.95View SEC Filing  
2/25/2016Graham Peter LidgardInsiderSell2,997$5.52$16,543.44View SEC Filing  
2/25/2016Maneesh AroraCOOSell4,099$5.52$22,626.48View SEC Filing  
2/23/2016Graham Peter LidgardInsiderSell2,411$6.39$15,406.29View SEC Filing  
2/23/2016Kevin T ConroyCEOSell6,866$6.39$43,873.74View SEC Filing  
2/23/2016Maneesh AroraCOOSell2,556$6.39$16,332.84View SEC Filing  
1/11/2016David ThompsonDirectorBuy15,000$6.99$104,850.00View SEC Filing  
2/26/2015Graham Peter LidgardDirectorSell3,938$23.44$92,306.72View SEC Filing  
2/26/2015Kevin T ConroyCEOSell8,425$23.44$197,482.00View SEC Filing  
2/26/2015Maneesh AroraCOOSell3,895$23.44$91,298.80View SEC Filing  
2/24/2015Graham Peter LidgardDirectorSell4,037$22.90$92,447.30View SEC Filing  
2/24/2015Kevin T ConroyCEOSell9,798$22.90$224,374.20View SEC Filing  
2/24/2015Maneesh AroraCOOSell2,995$22.90$68,585.50View SEC Filing  
1/2/2015Graham Peter LidgardInsiderSell3,363$26.72$89,859.36View SEC Filing  
1/2/2015Kevin T ConroyCEOSell9,484$26.72$253,412.48View SEC Filing  
1/2/2015Maneesh AroraCOOSell2,495$26.72$66,666.40View SEC Filing  
10/29/2014Graham Peter LidgardInsiderSell8,015$24.68$197,810.20View SEC Filing  
7/25/2014Graham Peter LidgardVPSell11,081$15.99$177,185.19View SEC Filing  
7/25/2014Kevin T ConroyCEOSell11,336$15.99$181,262.64View SEC Filing  
7/25/2014Maneesh AroraCOOSell9,291$15.99$148,563.09View SEC Filing  
5/5/2014William MeganSVPBuy10,000$11.79$117,900.00View SEC Filing  
2/24/2014Graham Peter LidgardVPSell3,160$14.07$44,461.20View SEC Filing  
2/24/2014Kevin ConroyCEOSell8,708$14.07$122,521.56View SEC Filing  
2/24/2014Maneesh AroraCOOSell2,662$14.07$37,454.34View SEC Filing  
1/2/2014Graham Peter LidgardVPSell10,288$11.96$123,044.48View SEC Filing  
1/2/2014Kevin ConroyCEOSell26,379$11.96$315,492.84View SEC Filing  
1/2/2014Maneesh AroraCOOSell8,627$11.96$103,178.92View SEC Filing  
10/28/2013Graham Peter LidgardVPSell7,430$11.07$82,250.10View SEC Filing  
9/20/2013Sally CrawfordDirectorSell25,000$12.19$304,750.00View SEC Filing  
11/2/2012Kevin T ConroyCEOBuy2,000$9.13$18,260.00View SEC Filing  
11/2/2012Maneesh AroraCFOBuy1,000$9.04$9,040.00View SEC Filing  
11/1/2012Lionel SterlingDirectorBuy5,500$9.08$49,940.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for EXACT Sciences (NASDAQ:EXAS)
Latest Headlines for EXACT Sciences (NASDAQ:EXAS)
finance.yahoo.com logoThese Stocks Have Doubled in 2017
finance.yahoo.com - May 23 at 12:04 PM
finance.yahoo.com logoETFs with exposure to EXACT Sciences Corp. : May 19, 2017
finance.yahoo.com - May 19 at 4:53 PM
americanbankingnews.com logoTraders Buy Large Volume of Put Options on EXACT Sciences (EXAS)
www.americanbankingnews.com - May 17 at 9:20 AM
americanbankingnews.com logoQ3 2017 Earnings Forecast for EXACT Sciences Co. Issued By Leerink Swann (EXAS)
www.americanbankingnews.com - May 17 at 8:22 AM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Stock Rating Upgraded by Vetr Inc.
www.americanbankingnews.com - May 17 at 12:32 AM
finance.yahoo.com logoAnalyst Leaves Exact Sciences CEO Meeting With 'Fortified Confidence' Despite Recent Controversy
finance.yahoo.com - May 16 at 10:14 PM
seekingalpha.com logoBiotech Forum Daily Digest: Citron Targets Exact Sciences. Spotlight On Axsome Therapeutics
seekingalpha.com - May 16 at 11:48 AM
marketwatch.com logoUPDATE: Exact Sciences Corp. stock drops 3% after short-seller Citron Research targets its colon cancer test
www.marketwatch.com - May 16 at 11:48 AM
streetinsider.com logoExact Sciences (EXAS) Mentioned Cautiously at Citron Research
www.streetinsider.com - May 16 at 11:48 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Exact Sciences Corporation (EXAS)
finance.yahoo.com - May 16 at 11:48 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Exact Sciences Corporation and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 16 at 11:48 AM
finance.yahoo.com logoWhy One Analyst Says Citron Got Exact Sciences Wrong
finance.yahoo.com - May 16 at 11:48 AM
americanbankingnews.com logoEXACT Sciences' (EXAS) Buy Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 16 at 10:18 AM
benzinga.com logoExact Sciences Plunges With Negative Citron Assessment Of 'Poop In A Box' Diagnostics
www.benzinga.com - May 15 at 4:48 PM
finance.yahoo.com logoShort-seller's bear debate on Exact Sciences
finance.yahoo.com - May 15 at 4:48 PM
finance.yahoo.com logoFamed short-seller Andrew Left battles the CEO of his lat...
finance.yahoo.com - May 15 at 4:48 PM
finance.yahoo.com logoExact Sciences CEO and short-seller go mano-a-mano on CNBC, stock pares losses
finance.yahoo.com - May 15 at 4:48 PM
finance.yahoo.com logoEXACT (EXAS) ALERT: J&W Investigates Exact Sciences; Encourages Investors to Contact the Firm
finance.yahoo.com - May 15 at 4:48 PM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Exact Sciences Corporation
finance.yahoo.com - May 15 at 4:48 PM
finance.yahoo.com logoExact Sciences: Nothing to See Here?
finance.yahoo.com - May 15 at 4:48 PM
finance.yahoo.com logoThe short seller who uncovered Valeant has found his next target in health care
finance.yahoo.com - May 15 at 4:48 PM
finance.yahoo.com logoExact Sciences: Signs Say…Sticky?
finance.yahoo.com - May 15 at 11:36 AM
finance.yahoo.com logoExact Sciences Corp. stock drops 6% after short-seller Citron Research targets its colon cancer test
finance.yahoo.com - May 15 at 11:36 AM
finance.yahoo.com logoShort Covering Could Fuel More Gains For EXACT Sciences Stock
finance.yahoo.com - May 12 at 5:40 PM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Rating Increased to Buy at Vetr Inc.
www.americanbankingnews.com - May 11 at 12:30 AM
finance.yahoo.com logoETFs with exposure to EXACT Sciences Corp. : May 8, 2017
finance.yahoo.com - May 8 at 4:57 PM
americanbankingnews.com logo Brokerages Expect EXACT Sciences Co. (EXAS) to Post -$0.37 Earnings Per Share
www.americanbankingnews.com - May 8 at 4:14 PM
americanbankingnews.com logoAnalysts Set EXACT Sciences Co. (EXAS) Target Price at $26.33
www.americanbankingnews.com - May 6 at 12:50 AM
finance.yahoo.com logoOne Tiny Number Hints At How Big Exact Sciences' Opportunity Is
finance.yahoo.com - May 5 at 5:20 PM
finance.yahoo.com logoExact Sciences Is Rocketing Higher By as Much as 12% -- Here's Why
finance.yahoo.com - May 5 at 5:20 PM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - May 5 at 4:24 PM
fool.com logoWhat's Behind Exact Sciences Corp. Soaring 27.1% in April? -- The ... - Motley Fool
www.fool.com - May 4 at 10:16 PM
finance.yahoo.com logoCramer's lightning round: Slow and steady wins the race in pharma
finance.yahoo.com - May 3 at 9:58 PM
americanbankingnews.com logoVery Favorable Press Coverage Somewhat Likely to Impact EXACT Sciences (EXAS) Stock Price
www.americanbankingnews.com - May 3 at 11:42 AM
finance.yahoo.com logoWhat's Behind Exact Sciences Corp. Soaring 27.1% in April?
finance.yahoo.com - May 2 at 8:01 PM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 2 at 4:26 PM
americanbankingnews.com logoQ1 2019 Earnings Forecast for EXACT Sciences Co. (EXAS) Issued By Leerink Swann
www.americanbankingnews.com - May 1 at 2:36 PM
americanbankingnews.com logoGoldman Sachs Group Inc Reaffirms "Neutral" Rating for EXACT Sciences Co. (EXAS)
www.americanbankingnews.com - May 1 at 11:52 AM
americanbankingnews.com logoFY2017 Earnings Estimate for EXACT Sciences Co. Issued By William Blair (EXAS)
www.americanbankingnews.com - May 1 at 10:13 AM
finance.yahoo.com logoExact Sciences to participate in Bank of America Merrill Lynch Healthcare Conference
finance.yahoo.com - May 1 at 8:49 AM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Rating Lowered to Sell at Vetr Inc.
www.americanbankingnews.com - April 30 at 10:51 AM
americanbankingnews.com logoEXACT Sciences (EXAS) Receiving Very Favorable Press Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 9:28 AM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Given a $38.00 Price Target by Leerink Swann Analysts
www.americanbankingnews.com - April 29 at 12:46 PM
americanbankingnews.com logoResearch Analysts Set Expectations for EXACT Sciences Co.'s FY2018 Earnings (EXAS)
www.americanbankingnews.com - April 28 at 11:34 PM
fool.com logoWhy PayPal Holdings, Nokia, and Exact Sciences Jumped Today ... - Motley Fool
www.fool.com - April 28 at 11:10 PM
americanbankingnews.com logoShort Interest in EXACT Sciences Co. (EXAS) Drops By 3.3%
www.americanbankingnews.com - April 28 at 10:54 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: EXACT Sciences and Celgene
finance.yahoo.com - April 28 at 7:53 AM
americanbankingnews.com logoEXACT Sciences Co. (EXAS) Price Target Increased to $40.00 by Analysts at Cowen and Company
www.americanbankingnews.com - April 27 at 6:02 PM
seekingalpha.com logoEXACT Sciences (EXAS) Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 5:39 PM
finance.yahoo.com logoMDxHealth and Exact Sciences Sign Collaboration Agreement
finance.yahoo.com - April 27 at 5:39 PM



EXACT Sciences (EXAS) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff